Drug Trial Radar · NCT07345689
A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 30, 2026
Primary completion
Oct 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the pharmacokinetic profile and safety of anaprazole sodium in adult subjects, particularly including the elderly and those with renal or hepatic impairment.
Conditions
- Hepatic Insufficiency
- Renal Insufficiency
- Elderly
Interventions
Anaprazole Sodium enteric-coated tabletDrug
20 mg single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Up to 48 hours from anaprazole sodium administration
- TmaxTime frame: Up to 48 hours from anaprazole sodium administration
- AUC0-tTime frame: Up to 48 hours from anaprazole sodium administration
- AUC0-∞Time frame: Up to 48 hours from anaprazole sodium administration
- t1/2Time frame: Up to 48 hours from anaprazole sodium administration
- CL/FTime frame: Up to 48 hours from anaprazole sodium administration
- Vz/FTime frame: Up to 48 hours from anaprazole sodium administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.